Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulators: current and future development and application.

M A Chirigos1

  • 1U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011.

Thymus
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hepatitis B virus and the inflammatory/immunologic response (II): a new opportunity for the treatment of chronic hepatitis B and a suggestion for the treatment of other persistent viral diseases].

Revista espanola de enfermedades digestivas·1998
Same author

[Hepatitis B virus (HBV) and the inflammatory/immune response. I. The natural environment of the antigen presentation and immunologic chaos induced by the virus].

Revista espanola de enfermedades digestivas·1998
Same author

Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes.

Immunopharmacology and immunotoxicology·1995
Same author

AM3, an adjuvant to hepatitis B revaccination in non-responder healthy persons.

Journal of hepatology·1995
Same author

Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections.

Antiviral research·1994
Same author

Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents.

AIDS research and human retroviruses·1993
Same journal

Detection of Fas and its ligand, FasL, in mouse thymus by in situ hybridization.

Thymus·1997
Same journal

Nonresponsiveness and susceptibility to CTLA-4 of antigen-exposed CD4 T cells are not regulated by the Bcl-2 family of apoptotic mediators, but can be restored by IL-2.

Thymus·1997
Same journal

Modulation of cytokine gene expression by thymic lympho-stromal cell to cell interaction: effect of retinoic acid.

Thymus·1997
Same journal

Anti-NK antibodies injected into recipient mice enhance engraftment and chimerism after allogeneic transplantation of fetal liver stem cells.

Thymus·1997
Same journal

Presence of nerve growth factor in the thymus of prenatal, postnatal and pregnant rats.

Thymus·1997
Same journal

Loss of T-cell cytotoxic responses in the course of HIV-1 infection.

Thymus·1997
See all related articles

Immunomodulators, including biologicals, chemicals, and cytokines, are vital for treating immune-related diseases. Future research will focus on purifying these agents for more effective and less toxic therapies against various human and animal conditions.

Area of Science:

  • Immunology
  • Pharmacology
  • Biochemistry

Background:

  • Immunomodulators are established therapeutic agents for various diseases.
  • They are particularly effective in managing immunodeficiency-related conditions.
  • Advancements in purification and synthesis are crucial for future development.

Purpose of the Study:

  • To review the role and potential of different classes of immunomodulators in disease treatment.
  • To highlight the importance of defining active moieties and characterizing novel biological agents.
  • To emphasize the synergistic effects of immunomodulators with other therapeutic modalities.

Main Methods:

  • Review of existing literature on immunomodulators (biological, chemical, cytokines).
  • Analysis of successful therapeutic applications, such as BCG in bladder cancer and Levamisole with 5-FU in colorectal cancer.

Related Experiment Videos

  • Discussion of advancements in cytokine research, including cloning and recombinant technologies.

    • Main Results:

    • Biological agents like BCG have shown success in treating superficial transitional cell bladder carcinoma with lower toxicity than cytotoxic agents.
    • Chemically defined immunomodulators, such as Levamisole, demonstrate additive effects when combined with chemotherapy.
    • Recombinant cytokines, enabled by cloning technology, have expanded understanding and therapeutic applications.

    Conclusions:

    • Immunomodulators (biologicals, chemical, cytokines) are essential in treating numerous human and animal diseases.
    • Further research into purifying and defining biological agents and cytokines will enhance their therapeutic efficacy.
    • Combining immunomodulators with other treatments offers a promising strategy for improved patient outcomes.